Increased demand for fertility treatment is driving the valuation of medical textiles. This trend is specifically noted in the context of investments centered on markets including Montagu, Kohlberg, and Arlington. Amulet's CV in US Fertility is mentioned in connection with this development. The core link established is between fertility treatment demand and the market for medical textiles. The exact mechanism linking these factors is not detailed in the provided text.

The narrative connects a specific market trend—increased demand for fertility treatment—to an investment focus on medical textiles and a specific company valuation (Amulet's CV). The underlying tension lies in how broad consumer/medical demand translates into tangible asset valuation within the supply chain. A potential gap exists between high-level market demand and the specific, named financial or physical instruments driving the betting mentioned. What assumptions about supply chain elasticity and investment correlation are being leveraged here? Does the focus on textiles serve as a proxy for overall healthcare spending in this sector, or is it an isolated market indicator? What factors influence the premium assigned to medical textile investments versus direct fertility treatment growth?